WEBVTT

1
00:00:00.320 --> 00:00:04.070
(gentle environmental music)

2
00:00:05.350 --> 00:00:06.680
<v ->Let's start with the big picture.</v>

3
00:00:06.680 --> 00:00:09.260
What excites you most about the field of CGT,

4
00:00:09.260 --> 00:00:11.410
and what do you see as the major challenges

5
00:00:11.410 --> 00:00:13.560
over the next three to five years?

6
00:00:13.560 --> 00:00:16.350
<v ->Well, I think there are couple of exciting areas.</v>

7
00:00:16.350 --> 00:00:19.970
One in on the cell-based gene therapy end of things,

8
00:00:19.970 --> 00:00:22.650
the other is on directly administrated gene therapy.

9
00:00:22.650 --> 00:00:24.420
For cell-based gene therapy,

10
00:00:24.420 --> 00:00:27.830
that is the chimeric antigen receptor, T-cells primarily,

11
00:00:27.830 --> 00:00:32.830
we've really seen progress there with the manufacturing,

12
00:00:34.040 --> 00:00:35.700
the development of these,

13
00:00:35.700 --> 00:00:40.170
so they're becoming more routinely

14
00:00:40.170 --> 00:00:42.690
progressing through the development process.

15
00:00:42.690 --> 00:00:46.510
So that we see, now we're starting to see them appear,

16
00:00:46.510 --> 00:00:50.050
multiple approvals per year,

17
00:00:50.050 --> 00:00:54.070
branching out from just the one target.

18
00:00:54.070 --> 00:00:55.968
And then, I think on

19
00:00:55.968 --> 00:01:00.590
the directly administered gene therapies,

20
00:01:00.590 --> 00:01:02.140
we've seen a lot of progress.

21
00:01:02.140 --> 00:01:04.190
I mean, we're starting to get into bumping

22
00:01:04.190 --> 00:01:07.310
into some toxicities, understandably so,

23
00:01:07.310 --> 00:01:11.080
but we're also seeing progress made

24
00:01:11.080 --> 00:01:15.110
in terms of positive results,

25
00:01:15.110 --> 00:01:19.210
improvements in manufacturing technologies,

26
00:01:19.210 --> 00:01:24.060
and also, starting to see branching out

27
00:01:24.060 --> 00:01:28.570
into people thinking about using things that are

28
00:01:28.570 --> 00:01:30.350
as kind of cutting edge

29
00:01:30.350 --> 00:01:35.347
as directly administered, or in vivo genome editing,

30
00:01:35.347 --> 00:01:39.550
which once we get over the issues with off target effects,

31
00:01:39.550 --> 00:01:41.703
could be really transformative.